Encouraging American Innovation & Competing in a
Global Economy – Health Care
Wednesday, April 13, 3 p.m. EDT
Health innovations continue to improve, and even save, lives. Sometimes these innovations can reduce health care costs, but in other cases, although highly effective, innovations may be associated with higher costs. State policies can promote the economic success of the health industry sector, as well as contribute to economic development by attracting this sector of business. Learn about innovative business practices under way in the health industry that are benefiting the current economic recovery and improving health outcomes.
Peter M. Pellerito, vice president for state government relations and alliance development, Biotechnology Industry Organization, View Bio >>
Christine Grygon, head, BI Partnering, Boehringer Ingelheim Pharmaceuticals
View Bio >>
Chad Cornell, vice president, Medtronic Business Development View Bio >>
CSG Resolution Supporting Efforts to Promote Health Information Technology, adopted Nov. 14, 2009
Peter M. Pellerito is vice president for State Government Relations and Alliance Development for Biotechnology Industry Organization, which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
Pellerito has served as a consultant to BIO since 1995, and has written and contributed extensively to numerous bioscience economic policy publications. He has served as an industry member representative of BIO’s Federal Government Relations and State Government Relations Committees, as well as an economic development and university outreach consultant. Pellerito’s experience also includes senior government relations posts at the University of Michigan. He received a B.A. from California State University and a M.A. from Michigan State University.
Chris Grygon is head of BI Partnering in the Business Development and Licensing group at Boehringer Ingelheim Pharmaceuticals in Ridgefield, Conn. During the past year she was also acting head, Global Licensing-Oncology, where she had oversight for strategy and evaluation around external alliances for Boehringer’s oncology portfolio. Prior to that, she was head of Technology Investments for North America, also in the Business Development and Licensing area, responsible for sourcing external innovation to support Boehringer’s Research and Development functions. She has held positions as executive director of Biologics and Biomolecular Sciences in the Research and Development function, where she established and led a technology infrastructure group in support of the discovery of new protein therapeutics in collaboration with Boehringer’s research and development group in North America and manufacturing groups in Europe. Her team was also responsible for enabling specialized technology platforms to facilitate innovative drug discovery research for BI worldwide.
Grygon obtained her B.S. in chemistry from the University of Delaware and her M.A. and Ph.D. in chemistry from Princeton University. She is an inventor on five patents and an author on more than 23 peer-reviewed scientific publications. She was a 2008 finalist for the Connecticut Technology Council Women of Innovation, Research Innovation and Leadership Award.
In January of 2009 Chad Cornell was appointed vice president of Medtronic Business Development. In this role, he is responsible for oversight and coordination of Medtronic’s Mergers and Acquisitions, Licensing and Minority Investment activity.
Cornell joined the Medtronic Business Development group in April 2005 as a director and was subsequently promoted to senior director in February 2008. In this role, he was responsible for supporting Medtronic business units in effecting strategic transactions for Medtronic.
Prior to joining Corporate Development, Cornell was legal counsel – M&A, responsible for advising Corporate Development on strategic transactions across Medtronic. Prior to joining Medtronic in 2003, Chad spent approximately five years as an associate attorney at Sidley & Austin in Chicago, Ill., working on mergers and acquisitions and securities offerings.
Cornell received his undergraduate degree in accounting from Marquette University and a Juris Doctorate from the University of Pennsylvania. He has also successfully completed Certified Public Accountant and Chartered Financial Analyst examinations.